An antisense technology for silencing genes that contribute to hampered insulin production may help treat Type 2 diabetes.

United Therapeutics signed on to a collaboration with Israel-based CollPlant for the development of 3D-printed lung transplants.

Bayer and Loxo Oncology have published the latest updated data for larotrectinib at ESMO.

The highest dose of the anti-GM-CSF antibody failed to beat the placebo on a disease activity score, but GSK plans to run more trials nonetheless.

Viseon received a 510(k) clearance from the FDA for its Voyant System for minimally invasive spine surgeries, including HD imaging and illumination.

Updated data show an objective response rate of 13% across 62 patients; treatment-naïve patients fared better than relapsed or refractory patients.

New data has shown positive results from a phase 3 looking at Novartis’ investigational oncology drug in combo with an old AZ breast cancer drug.

The multiyear contract will employ Congenica’s Sapientia genome interpretation software platform.